PlexBio Valuation

Q: What is the Fair Price of 6572 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

6572 (NT$12.4) is trading below our estimate of [[fair value]] (NT$111.22)

Is 6572 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6572 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6572 (NT$12.4) is trading below our estimate of fair value (NT$111.22)

Significantly Below Fair Value: 6572 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6572?

Key metric: As 6572 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6572. This is calculated by dividing 6572's market cap by their current revenue.
What is 6572's PS Ratio?
PS Ratio	12.4x
Sales	NT$103.64m
Market Cap	NT$1.29b

6572 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	7.6x
Enterprise Value/EBITDA	-11x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 6572's PS Ratio compare to its peers?

The above table shows the PS ratio for 6572 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.2x
4121 Rossmax International	0.4x	n/a	NT$1.4b
6730 Lagis Enterprise	2.6x	n/a	NT$1.2b
3184 MicroBase Technology	4.8x	n/a	NT$1.0b
4744 CVC Technologies	0.9x	n/a	NT$1.1b
6572 PlexBio	12.4x	n/a	NT$1.3b

Price-To-Sales vs Peers: 6572 is expensive based on its Price-To-Sales Ratio (12.4x) compared to the peer average (2.2x).

Price to Sales Ratio vs Industry

How does 6572's PS Ratio compare vs other companies in the TW Medical Equipment Industry?

2 Companies	Price / Sales	Estimated Growth	Market Cap
4116 BenQ Medical Technology	0.5x	n/a	US$66.23m
4121 Rossmax International	0.4x	n/a	US$44.47m

No more companies available in this PS range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 6572 is expensive based on its Price-To-Sales Ratio (12.4x) compared to the TW Medical Equipment industry average (2.8x).

Price to Sales Ratio vs Fair Ratio

What is 6572's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6572 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	12.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6572's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Universal Vision Biotechnology

NT$18.2b

Operates a chain of eye care clinics in Taiwan and China.

3218

NT$214.50

3.6%

-27.3%

Ma Kuang Healthcare Holding

NT$1.3b

An investment holding company, provides medical services in Taiwan and internationally.

4139

NT$29.95

-1.3%

-18.8%

Crystalvue Medical

NT$2.3b

Designs, manufactures, and sells ophthalmic medical equipment worldwide.

6527

NT$89.40

-0.1%

2.2%